Hironoshin Nomura is a member of Mizuho’s industry-leading Japan Health Care team, and is Mizuho’s lead analyst for Japanese biotech. In that role, he has met with all 44 of Japan’s publicly listed biotech companies, and publishes official research reports (including investment ratings and price objectives) on over two-thirds of the Japanese biotech industry by market capitalisation. He was recognised as the Number 1 stockpicker in Japanese biotech in the 2016 Thomson Reuters Analyst Awards.
Hironoshin began his career in Japan biotech at the Strategic Consulting Group within the Mitsubishi Research Institute, working with private sector Japanese biotech companies on their M&A and strategic business plans, and advising the Japanese government on regulations to promote the growth of Japanese regenerative medicine and cell therapy technologies.
Hironoshin has a MSc and BSc in Pharmaceutical Science, having studied for six years at Tohoku University’s School of Pharmaceutical Science.